| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3164028 | Oral Oncology | 2014 | 9 Pages |
Abstract
Dose-escalated IMRT at DL2 achieves higher 5-year local control, larynx preservation and survival rates with acceptable late toxicity. Recruitment into a Cancer Research UK Phase III study (ART-DECO), with DL2 as the experimental arm, is ongoing.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Dorothy M. Gujral, Aisha B. Miah, Shankar Bodla, Thomas M. Richards, Liam Welsh, Ulrike Schick, Ceri J. Powell, Catharine H. Clark, Margaret A. Bidmead, Lorna Grove, Teresa Guerrero-Urbano, Shreerang A. Bhide, Kate L. Newbold, Kevin J. Harrington,